Clinical Trial: Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07674745) titled 'Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis' on June 24.

Brief Summary: This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).

Study Start Date: Oct. 01, 2026

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis

Intervention: OTHER: Therapeutic Plasma Exchange

Removal of patient's plasma by mechanical means and replacement with saline and alb...